2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-mannopyranosyl chloride | 74081-14-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-mannopyranosyl chloride
• 英文别名: [(2R,3S,4R,5S,6R)-5-acetamido-3,4-diacetyloxy-6-chlorooxan-2-yl]methyl acetate
• CAS: 74081-14-4
• 化学式: C₁₄H₂₀ClNO₈
• 分子量: 365.768
• InChiKey: NAYYKQAWUWXLPD-ITGHMWBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-mannopyranosyl chloride 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 甲醇 、 乙腈 、 苯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-mannopyranosyl phosphate
  参考文献：
  名称：

  Yamazaki, Tatsumi; Warren, Christopher D.; Herscovics, Annette, Canadian Journal of Chemistry, 1981, vol. 59, p. 2247 - 2252

  摘要：

  DOI：
• 作为产物：
  描述：

  N-acetyl-D-mannosamine 、 乙酰氯 生成 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-mannopyranosyl chloride
  参考文献：
  名称：

  通过自由基方法对2-氨基-2-脱氧糖衍生物进行立体控制的烯丙基化11有关这项工作的初步报告，请参见参考文献[1]。

  摘要：

  摘要在对各种N-取代基和糖苷配基作为糖基自由基前体的比较研究中，已评估了2-氨基-2-脱氧糖的异源特异性1- C-烯丙基化的制备途径，该方法可有效捕获烯丙基三丁基锡中的烯丙基。当2-乙酰氨基-3,4,6-tri-O-时，以70％的收率获得3-（2-乙酰氨基-2-脱氧-α-d-吡喃葡萄糖基）-1-丙烯的三乙酸酯晶体4。在自由基条件下，用烯丙基三丁基锡处理乙酰基-2-脱氧-α-d-吡喃葡萄糖基氯（1），而相应的溴化物3仅生成恶唑烷衍生物。1的β-1-乙基黄原酸酯类似物给出4，但收率仅为25％。1的2-三氟乙酰酰胺基1-溴化物类似物也是有效的自由基来源，以60％的收率得到2-三氟乙酰氨基类似物8​​为4。经由4的2-对甲氧基苄叉亚氨基1-溴化物类似物方便地获得4的游离氨基类似物7。使用3,4,6-三-O-乙酰基-2-脱氧-2-邻苯二甲酰亚胺基-β-d-吡喃葡萄糖基溴化物作为自由基前体可以立体定向

  DOI：

  10.1016/s0008-6215(98)00141-4

文献信息

• [EN] N-GLYCOSYLATION OF PEPTIDES AND PROTEINS<br/>[FR] N-GLYCOSYLATION DE PEPTIDES ET DE PROTÉINES
  申请人：ISIS INNOVATION

  公开号：WO2015056011A1

  公开（公告）日：2015-04-23

  A process for the production of a glycoconjugate by N-glycosylation of a protein or peptide comprising the sequence D/E-X-N-X-S/T, wherein each X is the same or different and is any natural amino acid other than proline, wherein the process comprises reacting the protein or peptide with a polyisoprenyl pyrophosphate of formula (I), or a salt thereof, in the presence of PglB: (I) to produce the glycoconjugate comprising the protein or peptide having a saccharide [SI] linked to the asparagine in the sequence D/E-X-N-X-S/T. Polyisoprenylpyrophosphates used as substrates in the biocatalytic process are also provided, as well as certain glycoconjugates.

  一种通过蛋白质或肽的N-糖基化制备糖蛋白的方法，所述蛋白质或肽包括序列D/E-X-N-X-S/T，其中每个X相同或不同，是任何天然氨基酸，但不包括脯氨酸，该方法包括将蛋白质或肽与式(I)的聚异戊二烯基焦磷酸盐或其盐在PglB的存在下反应，以产生包含与序列D/E-X-N-X-S/T中的天冬氨酸连接的糖蛋白。还提供了作为生物催化过程中底物使用的聚异戊二烯基焦磷酸盐，以及某些糖蛋白。
• Delivery systems
  申请人：——

  公开号：US20040176281A1

  公开（公告）日：2004-09-09

  The invention relates to compounds which are useful in the delivery of a wide variety of therapeutically useful molecules. In particular, the invention relates to compounds which are able to act as carriers for therapeutically useful molecules, and to pharmaceutical agents comprising these carriers. The compounds of the invention comprise a mono- or oligosaccharide, a lipidic moiety, and optionally a linker and/or a spacer. The pharmaceutical agents of the invention are particularly useful for oral administration.

  本发明涉及一种在传递各种治疗有用分子方面有用的化合物。具体而言，本发明涉及能够作为治疗有用分子的载体的化合物，以及包含这些载体的制药剂。本发明的化合物包括单糖或寡糖、脂质基团，以及可选的连接物和/或间隔物。本发明的制药剂对于口服给药特别有用。
• METHOD OF COVALENTLY LINKING A CARBOHYDRATE OR POLYALKYLENE OXIDE TO A PEPTIDE, PRECURSORS FOR USE IN THE METHOD AND RESULTANT PRODUCTS
  申请人：MacMillan Derek

  公开号：US20100069607A1

  公开（公告）日：2010-03-18

  A glycopeptide of the formula S-L-X—P, wherein: S is selected from an optionally protected monosaccharide, an optionally protected polysaccharide, a polyalkylene oxide chain and a group of the formula II, wherein R 1 and R 3 are independently selected from H or Ac, R 4 is Ac, and R 2 is a group of formula IV, wherein R 7 and R 8 are each independently selected from an optionally protected monosaccharide and an optionally protected polysaccharide, A, B, C and D are each independently 1 or 2, and m is 1 to 5; -L- is a moiety of the formula III wherein R 5 and R 6 are independently selected from H and Me and n is 1 to 3; and P is a peptide chain containing at least one amino acid having on its side chain the atom X, wherein X is an oxygen, a sulphur atom or a —CH 2 — moiety.

  化合物为S-L-X—P的糖肽，其中：S选自可选择保护的单糖、可选择保护的多糖、聚烷氧基链和式II的基团，其中R1和R3各自独立地选自H或Ac，R4为Ac，R2为式IV的基团，其中R7和R8各自独立地选自可选择保护的单糖和可选择保护的多糖，A、B、C和D各自独立地为1或2，m为1到5；-L-为式III的基团，其中R5和R6各自独立地选自H和Me，n为1到3；P为含有至少一个侧链上有X原子的氨基酸的肽链，其中X为氧原子、硫原子或-CH2-基团。
• N-GLYCOSYLATION OF PEPTIDES AND PROTEINS
  申请人：ISIS INNOVATION LIMITED

  公开号：US20160257983A1

  公开（公告）日：2016-09-08

  A process for the production of a glycoconjugate by N-glycosylation of a protein or peptide comprising the sequence D/E-X—N—X—S/T, wherein each X is the same or different and is any natural amino acid other than proline, wherein the process comprises reacting the protein or peptide with a polyisoprenyl pyrophosphate of formula (I), or a salt thereof, in the presence of PglB: (I) to produce the glycoconjugate comprising the protein or peptide having a saccharide [SI] linked to the asparagine in the sequence D/E-X—N—X—S/T. Polyisoprenylpyrophosphates used as substrates in the biocatalytic process are also provided, as well as certain glycoconjugates.

  一种通过将具有序列D / E-X-N-X-S / T的蛋白质或肽N-糖基化来生产糖蛋白的方法，其中每个X相同或不同，是除脯氨酸以外的任何天然氨基酸，该过程包括在存在PglB的情况下，将蛋白质或肽与式（I）的多异戊烯基焦磷酸盐或其盐反应，以产生包含与序列D / E-X-N-X-S / T中的天冬氨酸连接的糖[SI]的蛋白质或肽的糖蛋白。还提供了用作生物催化过程中底物的多异戊烯基焦磷酸盐以及某些糖蛋白。
• Ellipticine derivative and production process thereof
  申请人：SUNTORY LIMITED

  公开号：EP0173462A2

  公开（公告）日：1986-03-05

  An ellipticine derivative having the general formula: wherein R represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 4 carbon atoms, or an acyloxy group having 2 to 7 carbon atoms; R2 represents an aldose residue, a deoxyaldose residue, an N-acylaminoaldose residue having a substituted acyl group with 2 to 4 carbon atoms bonded to the N atom, an aldohexuronic amide residue, and aldohexuronic acid residue, an acylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated N-acylaminoaldose residue having an amino group substituted with an acyl group with 2 to 4carbon atoms and having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an arylalkylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 7 to 8 carbon atoms, an arylalkylated N-acylaminoaldose residue having an amino group with an acyl group with 2 to 4 carbon atoms and having, substituted for the hydrogen of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms; and R3 represents a hydrogen atom, a linear, branched, cyclic, or cyclic-linear alkyl group having 1 to 5 carbon atoms; X0 represents a pharmaceutically acceptable inorganic or organic acid anion; and the bond represented by N⊕ - R2 in the general formula (I) represents a glycoside bond between a nitrogen atom in the 2-position of the ellipticine and a carbon atom in the 1-position of the sugar. These ellipticine derivatives have a strong antineoplastic or antitumor activity and, therefore, are expected to be effective as an antineoplastic or antitumor agent.

  一种具有通式的鞣花碱衍生物： 其中 R 代表氢原子、羟基、具有 1 至 4 个碳原子的烷氧基或具有 2 至 7 个碳原子的酰氧基； R2 代表醛糖残基、脱氧醛糖残基、N-酰氨基醛糖残基（其 N 原子上键有 2 至 4 个碳原子的取代酰基）、醛缩脲酰胺残基、醛缩脲酸残基、酰化醛糖残基（其糖羟基的氢原子被取代）、一种酰化脱醛糖残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化的 N-酰氨基醛糖残基，其氨基被 2 至 4 个碳原子的酰基取代，并具有 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代糖羟基的氢原子；酰化的醛缩酰胺残基，其具有一种酰化的醛缩己脲酰胺残基，其糖的羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化醛缩醛酸酯残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷基酰基或 7 至 9 个碳原子的芳基酰基取代、芳烷基化脱醛糖残基，其糖的羟基的氢原子被 7 至 8 个碳原子的烷酰基取代；芳烷基化 N-酰氨基醛糖残基，其氨基带有 2 至 4 个碳原子的酰基，并具有一种芳烷基化的醛缩脲酰胺残基，其氨基具有 2 至 4 个碳原子的酰基，并具有 7 至 8 个碳原子的芳烷基取代糖的羟基的氢原子、一种芳烷基化的醛缩脲酸酯残基，其糖的羟基的氢原子被具有 7 至 8 个碳原子的芳烷基取代；和 R3 代表氢原子、具有 1 至 5 个碳原子的直链、支链、环状或环状直链烷基； X0 代表药学上可接受的无机或有机酸阴离子；以及 通式（I）中 N⊕ - R2 所代表的键代表鞣花碱 2 位上的氮原子与糖 1 位上的碳原子之间的糖苷键。这些鞣花碱衍生物具有很强的抗肿瘤或抗肿瘤活性，因此有望成为有效的抗肿瘤或抗肿瘤药物。